A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With Teriflunomide, in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety
Latest Information Update: 04 Jun 2024
At a glance
- Drugs Evobrutinib (Primary) ; Teriflunomide
- Indications Multiple sclerosis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms evolutionRMS 1
- Sponsors Merck KGaA
Most Recent Events
- 31 May 2024 This study has been completed in Czech Republic (Global end date: 8 Mar 2024).
- 29 May 2024 This study has been completed in Bulgaria, according to European Clinical Trials Database record.
- 25 Apr 2024 Status changed from active, no longer recruiting to discontinued. (Results from the EVOLUTION clinical trials showed evobrutinib did not meet its primary endpointof annualized relapse rate for up to 156 weeks compared to oral teriflunomide in both studies.)